Neuronetics Inc (STIM) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate that Neuronetics’ vertical integration is beginning to translate into scale and cash efficiency, positioning the firm for sustained growth in the expanding TMS and psychedelic‑therapy markets.

Key Takeaways

• CEO transition to Dan Reavers effective March 23
• Revenue $41.8M, 86% jump including Greenbrook
• Gross margin fell to 52% due to lower‑margin clinics
• Positive Q4 operating cash flow achieved after integration
• COMP360 psilocybin Phase 3 positive, NDA planned 2026

Pulse Analysis

Neuronetics’ Q1 earnings underscore how strategic acquisitions can accelerate growth in the mental‑health device sector. By folding Greenbrook’s clinic network into its existing NeuroStar platform, the company more than doubled revenue year‑over‑year, while also expanding its reach into both TMS and esketamine (SPRAVATO) treatments. This integration has created a vertically integrated model that captures patient referrals, treatment delivery, and reimbursement, a rare combination that can drive higher utilization rates and improve cash conversion. The leadership change to Dan Reavers, a veteran of medical‑device commercialization, signals a focus on scaling this model and expanding market penetration, especially as insurance coverage for adolescent TMS widens.

Operational efficiencies are a central theme of Neuronetics’ roadmap. The firm introduced tablet kiosks, a digital patient portal, and AI‑enhanced benefits investigation tools to streamline intake and claims processing, directly addressing the labor‑intensive nature of clinic operations. While gross margin dipped to 52% because of Greenbrook’s lower‑margin services, the company expects margin recovery as product mix shifts toward higher‑margin NeuroStar systems and as workflow automation reduces overhead. The positive fourth‑quarter operating cash flow, after a prior negative cash burn, reflects these discipline measures and sets the stage for a projected cash‑flow turnaround in the second half of 2026.

Looking ahead, Neuronetics is betting on its pipeline to diversify revenue beyond traditional TMS. The partnership with COMPASS Pathways on the COMP360 psilocybin therapy has yielded encouraging Phase 3 data, with an NDA slated for year‑end. If approved, this psychedelic treatment could leverage the company’s existing REMS infrastructure, allowing rapid clinic rollout with limited capital outlay. Combined with robust guidance for double‑digit clinic revenue growth and modest NeuroStar system expansion, the firm is positioning itself at the intersection of established neuromodulation and emerging psychedelic therapeutics, a convergence that could reshape treatment‑resistant depression care.